McGuireWoods represented Titan Partners Group, a division of American Capital Partners, and several other clients in 11 capital markets transactions during the second half of the year.
McGuireWoods represented Titan as sole placement agent in a $50 million registered direct offering and concurrent private placement of common stock by Quantum Computing, an innovative, integrated photonics and quantum optics technology company. The transaction is expected to close on or before Dec. 12, 2024. The deal team included partner Stephen Older, Charlotte partner Carly Ginley, counsel Andrew Terjesen and associate Allison Lizotte.
In a transaction that closed Nov. 21, 2024, McGuireWoods represented Titan as sole bookrunner in an $8.2 million public offering of common stock by Modular Medical, an insulin delivery technology company. The deal team included Older, Ginley, Lizotte, counsel George Davis and associate Allyson Maur.
The firm also represented Titan as sole placement agent in a $40 million registered direct offering of common stock by Quantum Computing. The transaction closed Nov. 18, 2024. The McGuireWoods team was led by Older, Ginley, Terjesen and Davis.
And in a transaction that closed Sept. 26, 2024, the firm represented Titan as sole bookrunner in a $15 million public offering of common stock and pre-funded warrants by enVVeno Medical Corp., a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The McGuireWoods team included Older, Terjesen and associate Preston Williams.
Earlier this year, the firm represented Titan in a $22.4 million initial public offering by Actuate Therapeutics and an $11 million public offering of common stock by Gain Therapeutics.
In four separate deals, McGuireWoods advised clients in transactions that provided funding for innovative healthcare and life sciences companies.
McGuireWoods represented long-term client Newbridge Securities Corp. as exclusive placement agent in a $12.4 million private placement of common stock, pre-funded warrants and warrants by IN8bio, a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies. The deal closed Oct. 31, 2024. Older and Ginley led the McGuireWoods team, with support from associate Spencer Park. Earlier this year, the firm represented Newbridge in an $11 million private investment in private equity (PIPE) transaction by RenovoRx.
The firm advised Brookline Capital Markets as sole placement agent in a $1.275 million private placement of common stock and warrants by Protagenic Therapeutics, a leader in biopharmaceutical innovation. The deal closed on Nov. 4, 2024. The firm’s deal team included Older, Ginley and Maur. Earlier this year, the firm represented Brookline Capital Markets as exclusive placement agent in a $3 million private placement of common stock by Carmell Corp., a bio-aesthetics company focused on skin and hair health. The Carmell transaction was led by Older and counsel Felix Saratovsky.
The firm also represented the investors in a $6.5 million PIPE transaction of notes and common stock and an exchange offer of existing warrants and debt for common stock by Eterna Therapeutics, a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines. The deal closed on Oct. 29, 2024. The McGuireWoods team included Older, Terjesen, Saratovsky and Williams. The firm previously represented the investors in a series of investments in Eterna.
McGuireWoods represented long-term client Biofrontera, a biopharmaceutical company, in a private placement of a $4.2 million senior secured convertible note. The transaction closed Nov. 22, 2024. The deal team included Older, partner Benjamin Iselin, Terjesen and Park. McGuireWoods has served as go-to U.S. counsel for Biofrontera for the past seven years. Firm lawyers represented the company in its initial public offering and several other securities offerings, as well as the acquisition of dermatology company Cutanea Life Sciences. The firm also advised Biofrontera on U.S. securities law and regulatory issues and litigation matters.
Additional recent transactions include:
- Representing SinglePoint, a diversified holding company principally engaged through its subsidiaries in providing renewable energy solutions and energy-efficient applications, in a Regulation A offering of up to $75 million. The deal closed on Oct. 15, 2024, and was led by Older, Ginley and Park. The firm represented SinglePoint in its uplisting transaction last year.
- Representing Direct Digital Holdings, an end-to-end full-service digital advertising platform, in a $20 million equity line of credit financing provided by New Circle Principal Investments. The deal closed on Oct. 21, 2024, and was led by Older and Terjesen.
- Representing certain existing noteholders in a $50 million offering of senior secured notes by Vantage Drilling International, due February 2028. The deal closed on Oct. 30, 2024, and was led by Older and partner Jeffrey Goldfarb.
“We were pleased to help our clients execute these transactions and achieve their business objectives,” Older said. “These deals are a testament to the depth, talent and versatility of McGuireWoods’ securities and capital markets team on the issuer and underwriter side and in various industries.”
Original source can be found here.